Baricitinib - PharmaKB

Olumiant(baricitinib)

Baricitinib, Olumiant (baricitinib) is a small molecule pharmaceutical. Baricitinib was first approved as Olumiant on 2017-02-13. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1 and tyrosine-protein kinase JAK2. In addition, it is known to target cyclin-G-associated kinase, non-receptor tyrosine-protein kinase TYK2, BMP-2-inducible protein kinase, AP2-associated protein kinase 1, and tyrosine-protein kinase JAK3.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
musculoskeletal diseases	D009140
skin and connective tissue diseases	D017437
immune system diseases	D007154

Trade Name

FDA

EMA

Olumiant (discontinued: Baricitinib)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Baricitinib

Tradename	Company	Number	Date	Products
OLUMIANT	Eli Lilly	N-207924 RX	2018-05-31	3 products, RLD

Labels

FDA

EMA

Brand Name	Status	Last Update
baricitinib	Use Authorization	2022-05-10
olumiant	New Drug Application	2024-11-13

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
rheumatoid arthritis	EFO_0000685	D001172	M06.9

Agency Specific

FDA

EMA

Expiration	Code
BARICITINIB, OLUMIANT, ELI LILLY AND CO
2025-06-13	I-890
2025-05-10	I-891
2023-05-31	NCE

Patent Expiration

Patent	Expires	Flag	FDA Information
Baricitinib, Olumiant, Eli Lilly And Co
9089574	2032-11-30		U-3372
11045474	2032-11-30		U-3372
9737469	2031-11-02		U-3500
8158616	2030-06-08	DS, DP
8420629	2029-03-10		U-247

ATC Codes

L: Antineoplastic and immunomodulating agents

— L04: Immunosuppressants

— L04A: Immunosuppressants

— L04AA: Selective immunosuppressants

— L04AA37: Baricitinib

HCPCS

No data

Clinical

Clinical Trials

168 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Arthritis	D001168	EFO_0005856	M05-M14	—	4	14	8	10	36
Rheumatoid arthritis	D001172	EFO_0000685	M06.9	1	4	11	9	10	35
Covid-19	D000086382	—	U07.1	—	8	18	1	5	28
Dermatitis	D003872	—	L30.9	1	1	8	1	6	17
Atopic dermatitis	D003876	EFO_0000274	L20	—	1	8	1	6	16
Eczema	D004485	—	L30.9	—	1	8	1	3	13
Alopecia areata	D000506	EFO_0004192	L63	1	2	3	1	1	7
Alopecia	D000505	—	L64	1	2	3	1	1	7
Spondylarthritis	D025241	—	—	—	1	—	1	1	3
Spondylitis	D013166	—	M46.9	—	1	—	1	1	3

Show 4 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Syndrome	D013577	—	—	1	5	2	—	2	8
Pneumonia	D011014	EFO_0003106	J18	—	5	4	—	—	7
Skin diseases	D012871	—	L00-L99	—	3	2	—	1	5
Systemic lupus erythematosus	D008180	EFO_0002690	M32	—	1	3	—	—	4
Coronavirus infections	D018352	EFO_0007224	B34.2	—	2	2	—	—	4
Dermatomyositis	D003882	EFO_0000398	M33	—	2	1	—	1	4
Juvenile arthritis	D001171	EFO_1002007	M08	—	—	3	—	—	3
Vitiligo	D014820	EFO_0004208	L80	—	2	1	—	1	3
Respiratory distress syndrome	D012128	EFO_1000637	J80	—	—	2	—	—	2
Diabetes mellitus	D003920	EFO_0000400	E08-E13	—	1	1	—	—	2

Show 24 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hemorrhage	D006470	MP_0001914	R58	1	4	—	—	—	4
Kidney diseases	D007674	EFO_0003086	N08	—	3	—	—	—	3
Thrombocytopenic purpura idiopathic	D016553	EFO_0007160	D69.3	—	3	—	—	—	3
Thrombocytopenia	D013921	HP_0001873	D69.6	—	3	—	—	—	3
Cerebral hemorrhage	D002543	—	—	1	3	—	—	—	3
Depression	D003863	—	F33.9	—	1	—	—	1	2
Cognitive dysfunction	D060825	—	G31.84	1	1	—	—	1	2
Myositis	D009220	EFO_0000783	G72.49	—	2	—	—	—	2
Muscular diseases	D009135	EFO_0002970	G72.9	—	2	—	—	—	2
Graft vs host disease	D006086	—	D89.81	2	1	—	—	—	2

Show 54 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	16	—	—	—	—	16
Allergic contact dermatitis	D017449	—	L23	1	—	—	—	—	1
Hypersensitivity	D006967	EFO_0003785	T78.40	1	—	—	—	—	1
Contact dermatitis	D003877	—	L25	1	—	—	—	—	1
Delayed hypersensitivity	D006968	—	—	1	—	—	—	—	1
Liver diseases	D008107	EFO_0001421	K70-K77	1	—	—	—	—	1
Liver failure	D017093	—	K72.9	1	—	—	—	—	1
Hepatic insufficiency	D048550	—	—	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Pain	D010146	EFO_0003843	R52	—	—	—	—	1	1
Brain diseases	D001927	—	G93.40	—	—	—	—	1	1
Fatigue	D005221	—	R53.83	—	—	—	—	1	1
Rheumatic diseases	D012216	—	M79.0	—	—	—	—	1	1
Ankylosing spondylitis	D013167	EFO_0003898	M45	—	—	—	—	1	1
Respiratory insufficiency	D012131	—	J96.9	—	—	—	—	1	1
Eosinophilia	D004802	—	D72.1	—	—	—	—	1	1
Immunoglobulin g4-related disease	D000077733	—	D89.84	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Baricitinib
INN	baricitinib
Description	Baricitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis. It has a role as an antirheumatic drug, an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an anti-inflammatory agent, an immunosuppressive agent and an antiviral agent. It is a pyrrolopyrimidine, a member of pyrazoles, a member of azetidines, a sulfonamide and a nitrile.
Classification	Small molecule
Drug class	tyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1